Cue Biopharma Announces Strategic Prioritization Of Autoimmune Programs; Anticipates Annualized Capital And Workforce Requirements To Be Reduced By ~25%; Expects To Reduce Its FY25 Operating Expenses By ~25%, To A Projected Annual Cash Burn, Based...
Cue Biopharma Announces Strategic Prioritization Of Autoimmune Programs; Anticipates Annualized Capital And Workforce Requirements To Be Reduced By ~25%; Expects To Reduce Its FY25 Operating Expenses By ~25%, To A Projected Annual Cash Burn, Based...
Cue Biopharma Announces Strategic Prioritization Of Autoimmune Programs; Anticipates Annualized Capital And Workforce Requirements To Be Reduced By ~25%; Expects To Reduce Its FY25 Operating Expenses By ~25%, To A Projected Annual Cash Burn, Based Upon Current Assumptions, Of ~$30M
Cue biopharma宣佈重點優化自身的自身免疫項目，預計資本和工作力年平均需求將減少約25％；預計到2025財年營業費用將減少約25％，按照當前的假設，將會有約3000萬美元的預計年現金流失。
Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature
優先考慮自身的自體免疫計劃，旨在使有前途的臨床數據的腫瘤計劃繼續成熟。
- Company anticipates annualized capital and workforce requirements to be reduced by approximately 25 percent
- 公司預計資本和工作力年平均需求將減少約25％
BOSTON, July 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the strategic prioritization of its autoimmune programs and organizational restructuring to strengthen operational efficiencies while enabling its encouraging oncology survival data to continue to mature.
2024年7月25日，美國波士頓（GLOBE NEWSWIRE） - 生物製品公司Cue biopharma（NASDAQ：CUE）公佈了其自身免疫項目的戰略重點，並進行了組織重組以加強運營效率，同時使其令人鼓舞的腫瘤生存數據能夠繼續成熟。該公司開發了一種新型治療生物製品，能夠選擇性地參與和調節特定於疾病的T細胞。